loading
Lantern Pharma Inc stock is traded at $3.91, with a volume of 4,435. It is up +0.00% in the last 24 hours and up +25.71% over the past month. Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$4.01
Open:
$4.03
24h Volume:
4,435
Relative Volume:
0.03
Market Cap:
$42.82M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-2.1966
EPS:
-1.78
Net Cash Flow:
$-17.24M
1W Performance:
-0.50%
1M Performance:
+25.71%
6M Performance:
-11.87%
1Y Performance:
-13.02%
1-Day Range:
Value
$3.97
$4.07
1-Week Range:
Value
$3.835
$4.41
52-Week Range:
Value
$2.55
$6.118

Lantern Pharma Inc Stock (LTRN) Company Profile

Name
Name
Lantern Pharma Inc
Name
Phone
972-277-1136
Name
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Name
Employee
24
Name
Twitter
@lanternpharma
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
LTRN's Discussions on Twitter

Compare LTRN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LTRN
Lantern Pharma Inc
3.97 45.67M 0 -19.09M -17.24M -1.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
463.00 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
553.33 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.35 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
593.38 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
300.77 31.54B 3.81B -644.79M -669.77M -6.24

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-07-21 Initiated H.C. Wainwright Buy

Lantern Pharma Inc Stock (LTRN) Latest News

pulisher
02:40 AM

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors - BioSpace

02:40 AM
pulisher
12:51 PM

Lantern Pharma Strengthens Board with AI and Oncology Expert Dr. Lee T. Schalop - citybuzz -

12:51 PM
pulisher
Jul 28, 2025

What makes Lantern Pharma Inc. stock price move sharplyDaily Trading Outlook With Proven Results - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Lantern Pharma Appoints Dr. Lee Schalop To Board - citybiz

Jul 28, 2025
pulisher
Jul 28, 2025

What institutional investors are buying Lantern Pharma Inc. stockInvest confidently with professional market insights - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Lantern Pharma appoints biotech executive Lee Schalop to board By Investing.com - Investing.com Nigeria

Jul 28, 2025
pulisher
Jul 28, 2025

Lantern Pharma appoints biotech executive Lee Schalop to board - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

What institutional flow reveals about Lantern Pharma Inc.Portfolio Booster Strategy with Trend Confidence - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

How Lantern Pharma Inc. stock performs during market volatility Weekly Signal Report with Trend Summary - Newser

Jul 28, 2025
pulisher
Jul 27, 2025

What are the latest earnings results for Lantern Pharma Inc.Dynamic portfolio growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Lantern Pharma Inc. in the next 12 monthsBuild a diversified portfolio for risk mitigation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Lantern Pharma Inc. stock overvalued or undervaluedIdentify safe investments with exceptional yields - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is it the right time to buy Lantern Pharma Inc. stockExtraordinary market timing - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Lantern Pharma Inc. Stock Overbought or Oversold RSI Indicator AnalysisFree Stock Selection with 300% Return - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Investment Community - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

Intrinsic Value of Lantern Pharma Inc. Stock: Is It Undervalued or OvervaluedFree Discussion Group - Newser

Jul 27, 2025
pulisher
Jul 27, 2025

How Resilient Is Lantern Pharma Inc. Stock During Economic DownturnsHigh Potential Safe Trades - Newser

Jul 27, 2025
pulisher
Jul 26, 2025

Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Published on: 2025-07-26 01:13:11 - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Lantern Pharma Inc. stockRapid growth opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bellingham Herald

Jul 25, 2025
pulisher
Jul 25, 2025

Is Lantern Pharma Inc. a good long term investmentFree Stock Market Real-Time Monitoring - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Will Lantern Pharma Inc. stock benefit from interest rate changesExceptional gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

How Lantern Pharma Inc. stock performs during market volatilityBalanced Risk Reward Portfolio - Newser

Jul 24, 2025
pulisher
Jul 24, 2025

Why Lantern Pharma Inc. stock is on top investor watchlistsOverwhelming financial success - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Lantern Pharma Inc. Stock Analysis and ForecastBreakthrough stock performance - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Lantern Pharma Inc. stock priceTremendous gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma reports complete response in aggressive lymphoma patient - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma reports complete response in aggressive lymphoma patient By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial - Business Wire

Jul 23, 2025
pulisher
Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent For AI-Designed Cancer Drug LP-284 - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284 - The Globe and Mail

Jul 22, 2025
pulisher
Jul 21, 2025

Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus

Jul 21, 2025
pulisher
Jul 21, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus

Jul 21, 2025

Lantern Pharma Inc Stock (LTRN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lantern Pharma Inc Stock (LTRN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kreis Leslie W.
10% Owner
Jun 13 '25
Sale
3.09
40,000
123,600
49,957
Fletcher Aaron G.L.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Fletcher Aaron G.L.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Fletcher Aaron G.L.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Kreis Leslie W.
10% Owner
Jun 12 '25
Sale
3.38
60,647
204,987
51,860
Kreis Leslie W.
10% Owner
Jun 11 '25
Sale
3.40
950
3,230
54,746
Kreis Leslie W.
10% Owner
Jun 10 '25
Sale
3.40
16
54
54,791
Fletcher Aaron G.L.
10% Owner
May 27 '25
Sale
3.05
21,037
64,163
56,467
Fletcher Aaron G.L.
10% Owner
May 29 '25
Sale
3.03
20,200
61,206
54,792
Fletcher Aaron G.L.
10% Owner
May 28 '25
Sale
2.87
15,000
43,050
55,753
$22.69
price down icon 1.73%
$36.91
price down icon 0.55%
$102.76
price up icon 0.56%
$27.37
price down icon 0.04%
$112.01
price down icon 0.60%
biotechnology ONC
$301.40
price up icon 2.39%
Cap:     |  Volume (24h):